$3.83
3.04%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US49372L1008
Symbol
KZR

Kezar Life Sciences Inc Stock price

$3.83
-0.27 6.59% 1M
-1.87 32.81% 6M
-2.89 43.01% YTD
-2.18 36.23% 1Y
-94.67 96.11% 3Y
-42.97 91.82% 5Y
-173.67 97.84% 10Y
-173.67 97.84% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.12 3.04%
ISIN
US49372L1008
Symbol
KZR
Industry

Key metrics

Basic
Market capitalization
$28.1m
Enterprise Value
$-64.9m
Net debt
positive
Cash
$100.9m
Shares outstanding
7.3m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.0
P/B
0.3
Financial Health
Equity Ratio
80.8%
Return on Equity
-71.6%
ROCE
-
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-78.8m
Net Income
- | $-62.7m
Free Cash Flow
$-64.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | 11.6%
Net Income
- | 25.1%
Free Cash Flow
18.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-8.8
Short interest
10.3%
Employees
55
Rev per Employee
$0.0
Show more

Is Kezar Life Sciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Kezar Life Sciences Inc forecast:

6x Buy
60%
4x Hold
40%

Analyst Opinions

10 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy
60%
Hold
40%

Financial data from Kezar Life Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
37% 37%
-
- Research and Development Expense 49 49
43% 43%
-
-64 -64
38% 38%
-
- Depreciation and Amortization 1.04 1.04
3% 3%
-
EBIT (Operating Income) EBIT -65 -65
38% 38%
-
Net Profit -62 -62
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kezar Life Sciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kezar Life Sciences Inc Stock News

Neutral
Business Wire
6 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in two upcoming investor conferences taking place in September: Event: 2025 Wells Farg...
Neutral
Business Wire
21 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “We are on track with our clinical development and regulatory submi...
Neutral
Business Wire
about 2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase...
More Kezar Life Sciences Inc News

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Christopher Kirk
Employees 55
Founded 2015
Website kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today